SBIR/STTR Research Award
Nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias
Award amount
$1,895,558Program and phase
SBIR · Phase IIAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Crinetics Pharmaceuticals, Inc.
- Proposal award date
- 2018-06-06
- Contract end date
- 2020-05-31
- UEI
- MJZFLM2TGRZ8
- Solicitation number
- PA16-302
- Topic code
- 200
Research abstract
TBD
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Discovery of novel small molecule drugs for Cushing s disease
- Nonpeptide oral somatostatin agonists for congenital hyperinsulinemias
- Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists
- Nonpeptide Kisspeptin Antagonists for PCOS and HPG axis control
- Small molecule somatostatin agonists for neuropathic pain
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes
- Next-Gen Oral Therapeutics for Type 2 Diabetes
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism
- Development of novel therapeutics for obesity and type 2 diabetes
- Metrifonate local application for DFU treatment
Research funding history
11 SBIR/STTR records share this UEI (2010–2018). Reported award amounts total $10,323,814. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services